Amarin’s European Outlook Hinges on Recordati’s VAZKEPA Execution, Raising Commercial and IP Risk

Amarin Corporation Plc (AMRN) has disclosed a new risk, in the Corporate Activity and Growth category.

The analyst notes that Amarin’s revenue prospects in 59 European-focused countries are heavily contingent on Recordati’s execution under the 2025 licensing agreement for VAZKEPA. Any shortfall in obtaining or maintaining marketing authorizations, securing optimal pricing and reimbursement, or ensuring efficient supply management could materially constrain market access and sales.

He further observes that Recordati’s broad discretion over commercialization strategy, resource allocation, and handling of Amarin’s intellectual property introduces additional uncertainty. Strategic shifts, funding constraints, or corporate transactions at Recordati could reduce prioritization of VAZKEPA, leaving Amarin with lower-than-expected payments and diminished asset value compared with self-commercialization.

Overall, Wall Street has a Moderate Sell consensus rating on AMRN stock based on 1 Sell.

To learn more about Amarin Corporation Plc’s risk factors, click here.